Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Patient Advisory Board for Chronic Rhinosinusitis - A EUFOREA initiative.

Pugin B, Deneyer L, Bachert C, Alobid I, Bousquet J, De Carlo G, Fokkens WJ, Gane S, Hopkins C, Holzmeister C, Langdon C, Lourijsen ES, Lund VJ, Marien G, Mavris M, Mullol J, Pereira-Perez C, Tomazic PV, Vanderveken O, Hellings PW, Seys SF.

Rhinology. 2019 Apr 9. doi: 10.4193/Rhin19.012. [Epub ahead of print]

PMID:
30963145
2.

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma.

Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F.

Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257. Epub 2017 Oct 27.

3.

Marketing authorisation of orphan medicines in Europe from 2000 to 2013.

Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, Vamvakas S, Regnstrom J, Aarum S.

Drug Discov Today. 2018 Feb;23(2):424-433. doi: 10.1016/j.drudis.2017.10.012. Epub 2017 Oct 23. Review.

4.

Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators.

Postmus D, Mavris M, Hillege HL, Salmonson T, Ryll B, Plate A, Moulon I, Eichler HG, Bere N, Pignatti F.

Clin Pharmacol Ther. 2016 May;99(5):548-54. doi: 10.1002/cpt.332. Epub 2016 Feb 17.

PMID:
26715217
5.

Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Vaquer G, Rivière F, Mavris M, Bignami F, Llinares-Garcia J, Westermark K, Sepodes B.

Nat Rev Drug Discov. 2013 Apr;12(4):287-305. doi: 10.1038/nrd3831. Epub 2013 Mar 15. Review.

PMID:
23493083
6.

Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe.

Mavris M, Le Cam Y.

Mol Syndromol. 2012 Nov;3(5):237-43. doi: 10.1159/000342758. Epub 2012 Sep 13.

7.

European regulation on orphan medicinal products: 10 years of experience and future perspectives.

Committee for Orphan Medicinal Products and the European Medicines, Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N'Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Matulevičiene A, Metz H, Vincenti AC, Voordouw A, Dembowska-Bagińska B, Nunes AC, Saleh FM, Foltánová T, Možina M, Torrent i Farnell J, Beerman B, Mariz S, Evers MP, Greene L, Thorsteinsson S, Gramstad L, Mavris M, Bignami F, Lorence A, Belorgey C.

Nat Rev Drug Discov. 2011 May;10(5):341-9. doi: 10.1038/nrd3445. Review.

PMID:
21532564
8.

The Trw type IV secretion system of Bartonella mediates host-specific adhesion to erythrocytes.

Vayssier-Taussat M, Le Rhun D, Deng HK, Biville F, Cescau S, Danchin A, Marignac G, Lenaour E, Boulouis HJ, Mavris M, Arnaud L, Yang H, Wang J, Quebatte M, Engel P, Saenz H, Dehio C.

PLoS Pathog. 2010 Jun 10;6(6):e1000946. doi: 10.1371/journal.ppat.1000946.

9.

Characterization of genes involved in long-term bacteremia in mice by Bartonella birtlesii.

Mavris M, Saenz H, Monteil M, Boulouis HJ, Dehio C, Vayssier-Taussat M.

Ann N Y Acad Sci. 2005 Dec;1063:312-4. No abstract available.

PMID:
16481533
10.

Broad-range PCR-TTGE for the first-line detection of bacterial pathogen DNA in ticks.

Halos L, Mavris M, Vourc'h G, Maillard R, Barnouin J, Boulouis HJ, Vayssier-Taussat M.

Vet Res. 2006 Mar-Apr;37(2):245-53.

11.

A secreted anti-activator, OspD1, and its chaperone, Spa15, are involved in the control of transcription by the type III secretion apparatus activity in Shigella flexneri.

Parsot C, Ageron E, Penno C, Mavris M, Jamoussi K, d'Hauteville H, Sansonetti P, Demers B.

Mol Microbiol. 2005 Jun;56(6):1627-35.

12.

Analysis of virulence plasmid gene expression defines three classes of effectors in the type III secretion system of Shigella flexneri.

Le Gall T, Mavris M, Martino MC, Bernardini ML, Denamur E, Parsot C.

Microbiology. 2005 Mar;151(Pt 3):951-62.

PMID:
15758240
13.

Topological analysis of GtrA and GtrB proteins encoded by the serotype-converting cassette of Shigella flexneri.

Korres H, Mavris M, Morona R, Manning PA, Verma NK.

Biochem Biophys Res Commun. 2005 Mar 25;328(4):1252-60.

PMID:
15708010
14.

Microbial-gut interactions in health and disease. Epithelial cell responses.

Mavris M, Sansonetti P.

Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):373-86. Review.

PMID:
15123076
16.

Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus.

Mavris M, Page AL, Tournebize R, Demers B, Sansonetti P, Parsot C.

Mol Microbiol. 2002 Mar;43(6):1543-53.

17.

CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri.

Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ, Philpott DJ.

EMBO Rep. 2001 Aug;2(8):736-42. Epub 2001 Jul 19.

18.

Mechanism of bacteriophage SfII-mediated serotype conversion in Shigella flexneri.

Mavris M, Manning PA, Morona R.

Mol Microbiol. 1997 Dec;26(5):939-50.

19.

Characterization of the rfc region of Shigella flexneri.

Morona R, Mavris M, Fallarino A, Manning PA.

J Bacteriol. 1994 Feb;176(3):733-47.

20.

Effect of gliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus.

Phenekos C, Siafaka-Kapadai A, Trapali M, Botitsi E, Mavris M.

Metabolism. 1992 May;41(5 Suppl 1):30-2. No abstract available.

PMID:
1574012
21.

Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice.

Kelefiotis D, Lanara E, Vakirtzi-Lemonias C, Siafaka A, Mavris M, Lazanas M, Demopoulos CA.

Life Sci. 1988;42(6):623-33.

PMID:
3339951

Supplemental Content

Loading ...
Support Center